BioPharmSignal logoBioPharmSignal

Biotech News

FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints

Boston Scientific (BSX)Boston ScientificClinical readout

BSX (BSX) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is bsx.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

DNLIDenali Therapeutics2026-05-21 22:00 EST

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

BSXBoston Scientific2026-05-04 12:00 EST

Boston Scientific announces participation in Bernstein's 42nd Annual Strategic Decisions Conference and conference call discussing second quarter 2026 results

BSXBoston Scientific2026-03-30 10:45 EST

Boston Scientific receives FDA clearance for the Asurys™ Fluid Management System

SGHTSight Sciences2026-03-30 11:05 EST

Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury’s Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent

ANGOAngioDynamics2026-05-13 13:00 EST

AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer

CVRXCVRx2026-05-04 20:30 EST

CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population

AEMDAethlon Medical2026-07-13 12:01 EST

Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®

ICCMIceCure Medical2026-03-25 12:30 EST

IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates

AEMDAethlon Medical2026-03-24 12:01 EST

Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review

RXSTRxSight2026-04-08 20:05 EST

RxSight Highlights 300,000 Light Adjustable Lens Implant Milestone and Strong Scientific Presence at ASCRS 2026

View all latest news

Boston Scientific

Boston Scientific is a leading medical technology company with major exposure to interventional cardiology, electrophysiology, endoscopy, urology, and structural heart. The company is built around procedure-linked products that benefit from hospital utilization and physician adoption.

Recent company news

BSXBoston Scientific2026-05-19 10:31 EST

FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints

BSXBoston Scientific2026-05-18 11:00 EST

Boston Scientific enters into $2 billion accelerated share repurchase agreement

BSXBoston Scientific2026-05-18 10:30 EST

Boston Scientific announces strategic investment in MiRus LLC

BSXBoston Scientific2026-05-04 12:00 EST

Boston Scientific announces participation in Bernstein's 42nd Annual Strategic Decisions Conference and conference call discussing second quarter 2026 results

BSXBoston Scientific2026-04-26 17:00 EST

Data at Heart Rhythm 2026 highlight key Boston Scientific therapies

Stock data

Close
45.51 USD
Market cap
70.87B USD
Exchange
NYSE
Sector
Biopharma
Location
United States